Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27751008 | 0.86 | MPO (0.41) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL5953156 | 0.86 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL10271562 | 0.82 | ITK (0.43) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL14979246 | 0.80 | TSHR (0.54) | MAP2K4MAPK1MAPK6ITKHTR2A | |
| SCHEMBL30965223 | 0.80 | TSHR (0.54) | MAP2K4MAPK1MAPK6ITKHTR2A | |
| SCHEMBL3589720 | 0.79 | GSK3B (0.47) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL1140859 | 0.79 | MAP2K4 (0.39) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL5952447 | 0.79 | MAP2K4 (0.60) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL1271820 | 0.79 | PDPK1 (0.58) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL5952457 | 0.79 | FADS1 (0.45) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | MAP2K4 252/4885MAPK1 154/4885MAPK6 112/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | MAP2K4 376/4885MAPK1 23/4885MAPK6 103/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | MAP2K4 160/4885MAPK1 64/4885MAPK6 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.